{"url_path":"/sec/crbp/8-k/2026-05-14/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1595097/0001193125-26-222890-index.html","accession_number":"0001193125-26-222890","cik":"0001595097","ticker":"CRBP","issuer_name":"Corbus Pharmaceuticals Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1595097/0001193125-26-222890-index.html","primary_entity_key":"0001595097","primary_entity_name":"Corbus Pharmaceuticals Holdings, Inc."},"word_count":433,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nOn May 13, 2026, the Company held its annual meeting of stockholders (the “Annual Meeting”). The matters voted on at the Annual Meeting were: (1) the election of directors, (2) the approval of the 2024 Plan Amendment, (3) the ratification of the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026, (4) the approval, on an advisory basis, of the executive compensation of the Company’s named executive officers, and (5) the approval, on an advisory basis, of how often the Company will conduct an advisory vote on executive compensation. The final voting results were as follows:\n\n1. The election of each of Yuval Cohen, Rachelle Jacques, John Jenkins, Anne Altmeyer, Yong Ben, and Winston Kung as directors to hold office for a term of one year, until his or her successor is duly elected and qualified or he or she is otherwise unable to complete his or her term.\n\nThe votes were cast for this matter as follows:\n\n \n\nNominees\n\nVotes For\n\nVotes Withheld\n\nBroker Non-Votes\n\nYuval Cohen\n\n9,986,956\n\n87,114\n\n4,060,300\n\nRachelle Jacques\n\n9,647,139\n\n426,931\n\n4,060,300\n\nJohn Jenkins\n\n9,636,703\n\n \n\n437,367\n\n4,060,300\n\nAnne Altmeyer\n\n9,621,769\n\n \n\n452,301\n\n4,060,300\n\nYong Ben\n\n9,988,459\n\n85,611\n\n4,060,300\n\nWinston Kung\n\n9,979,901\n\n94,169\n\n4,060,300\n\n2. The proposal to approve the 2024 Plan Amendment, was approved based on the following votes:\n\nVotes For\n\nVotes Against\n\nAbstentions\n\nBroker Non-Votes\n\n5,950,038\n\n4,099,773\n\n24,259\n\n4,060,300\n\n3. The proposal to ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026, was approved based upon the following votes:\n\nVotes For\n\nVotes Against\n\nAbstentions\n\n14,102,264\n\n14,731\n\n17,375\n\n4. The proposal to vote, on an advisory basis, on the compensation of the Company’s named executive officers as described in the Company’s definitive proxy statement was approved based upon the following votes:\n\nVotes For\n\nVotes Against\n\nAbstentions\n\nBroker Non-Votes\n\n9,325,932\n\n721,442\n\n26,696\n\n4,060,300\n\n \n\n5. The votes were cast as follows with respect to the proposal to vote, on an advisory basis, on whether an advisory vote on executive compensation should occur every year, two years or three years. In accordance with the votes, an advisory vote to approve executive compensation will occur every year until the next required vote on the frequency of future advisory votes to approve executive compensation, or until the Company otherwise determines that a different frequency for such advisory votes is in the best interest of the Company:\n\nEvery Year\n\nEvery Two Years\n\nEvery Three Years\n\nAbstentions\n\n9,712,048\n\n151,354\n\n198,373\n\n12,295"}